Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
C/M CAPITAL PARTNERS, LP - 20 May 2025 SCHEDULE 13G Report for Biodexa Pharmaceuticals Plc Ordinary Shares, nominal value 0.00005 GBP per share (BDRX)
- Filing manager
- C/M CAPITAL PARTNERS, LP
- Reporting owner
- Jonathan Juchno
- Beneficially owned shares
- 1,752,390,000 shares
- Large-stake signal
-
Ownership
6.8%Beneficial ownership of this reported class.
Shares
1,752,390,000 sharesShares beneficially owned as disclosed.
Event date
20 May 2025Date tied to the ownership event or amendment.
Accepted by SEC
28 May 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 6.8%
- Symbol
- BDRX
- Shares outstanding
- 25,770,441,176 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 28 May 2025, 17:59:16 UTC
- Event date
- 20 May 2025
- Prior SEC filing
- 18 Feb 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
C/M CAPITAL PARTNERS, LP disclosed 6.8% ownership in Biodexa Pharmaceuticals Plc Ordinary Shares, nominal value 0.00005 GBP per share (BDRX) on 20 May 2025.
Key facts
- C/M CAPITAL PARTNERS, LP filed SCHEDULE 13G for Biodexa Pharmaceuticals Plc Ordinary Shares, nominal value 0.00005 GBP per share (BDRX).
- Disclosed ownership: 6.8%.
- Date of event: 20 May 2025.
Change
- Previous schedule filing date: 18 Feb 2025.
- Current filing was accepted on 28 May 2025, 17:59.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (8)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Cavalry Fund I LP | 5.7% | 1,460,870,000 | 0 | 1,460,870,000 | /s/ Thomas Walsh | By: Cavalry Fund I GP LLC, General Partner, By: Thomas Walsh, Manager | |
| C/M Capital Partners, LP | 5.7% | 1,460,870,000 | 0 | 1,460,870,000 | /s/ Thomas Walsh | Thomas Walsh, Partner | |
| Cavalry Investment Fund LP | 0.3% | 74,830,000 | 0 | 74,830,000 | /s/ Thomas Walsh | By: Cavalry Fund GP, LLC, General Partner, By: Thomas Walsh, Managing Member | |
| Cavalry Fund I Management LLC | 0.3% | 74,830,000 | 0 | 74,830,000 | /s/ Thomas Walsh | Thomas Walsh, Manager | |
| Mercer Street Global Opportunity Fund, LLC | 1.1% | 291,520,000 | 0 | 291,520,000 | /s/ Jonathan Juchno | By: NFSO, LLC, its General Partner, By: Jonathan Juchno, Authorized Representative | |
| Mercer Street Capital Partners, LLC | 1.1% | 291,520,000 | 0 | 291,520,000 | /s/ Jonathan Juchno | Jonathan Juchno, Authorized Representative | |
| Thomas Walsh | 6% | 1,535,700,000 | 0 | 1,535,700,000 | /s/ Thomas Walsh | Thomas Walsh, Individually | |
| Jonathan Juchno | 6.8% | 1,752,390,000 | 0 | 1,752,390,000 | /s/ Jonathan Juchno | Jonathan Juchno, Individually |
CIK / CUSIP context first